Announcement no. 01/2018 - Coloplast completes acquisition of SAS Lilial
10 Enero 2018 - 4:22AM
Announcement no. 01/2018 - Coloplast completes acquisition of SAS
Lilial
Announcement No.
01/2018
10 January 2018
Coloplast completes acquisition of SAS
Lilial
Coloplast has now completed the acquisition of
Lilial.All terms remain as stated in Coloplast’s stock exchange
announcement no. 13/2017 regarding the acquisition of Lilial and
Coloplast confirms the previously stated guidance for the financial
year 2017/18:
- The organic revenue growth guidance of ~7% is unchanged. The
growth in DKK of 5-6% based on spot rates as of 31 October 2017 is
expected to be ~1%-points higher.
- The EBIT margin guidance of 31-32% in constant exchange rates
and about 31% in DKK is unchanged.
The long-term guidance for the LEAD 20 strategy period until
fiscal year-end 2019/20 of 7-9% organic growth p.a. and an EBIT
margin of more than 30% in constant currencies is unchanged.
For more information on Lilial please refer to
www.lilial.fr.
Lars Rasmussen President & CEO
For further information, please contact
Investors and analysts Anders
Lonning-SkovgaardExecutive Vice President, CFOTel. 4911 1111
Ellen BjurgertDirector, Investor Relations Tel. 4911 1800 / 4911
3376 E-mail dkebj@coloplast.com
Press and the mediaLina DanstrupSenior Media
Relations Manager Tel. 4911 2607 E-mail dklina@coloplast.com
Websitewww.coloplast.com
AddressColoplast A/SHoltedam 1DK-3050
HumlebækDenmark
CVR NR. 69749917
This announcement is available in a Danish and an
English-language version. In the event of any discrepancies, the
Danish version shall prevail.
The Coloplast logo is a registered trademark of Coloplast A/S. ©
2018-01 All rights reserved. Coloplast A/S, 3050 Humlebæk,
Denmark.
Coloplast develops products and services that make life easier
for people with very personal and private medical conditions.
Working closely with the people who use our products, we create
solutions that are sensitive to their special needs. We call this
intimate healthcare.
Our business includes Ostomy Care, Urology Care, Continence Care
and Wound and Skin Care. We operate globally and employ about
11,000 people.
http://prlibrary-eu.nasdaq.com/Resource/Download/59c6e223-2fba-47c6-bafc-71ab4e6b67da